T. Seto , M. Shimokawa , R. Toyozawa , S. Sugawara , H. Hayashi , H. Murakami , T. Kato , S. Niho , M. Oki , H. Yoshioka , H. Daga , K. Azuma , S. Miura , K. Nishino , M. Satouchi , I. Okamoto , N. Yamamoto
{"title":"38P:阿特唑单抗联合贝伐单抗治疗PD-L1高表达非鳞状非小细胞肺癌患者的II期临床试验2年随访数据(WJOG10718L/@ Be Study)","authors":"T. Seto , M. Shimokawa , R. Toyozawa , S. Sugawara , H. Hayashi , H. Murakami , T. Kato , S. Niho , M. Oki , H. Yoshioka , H. Daga , K. Azuma , S. Miura , K. Nishino , M. Satouchi , I. Okamoto , N. Yamamoto","doi":"10.1016/S1556-0864(25)00233-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S34-S35"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"38P: Two years of follow-up data of a phase II clinical trial of atezolizumab with bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung cancer (WJOG10718L/@ Be Study)\",\"authors\":\"T. Seto , M. Shimokawa , R. Toyozawa , S. Sugawara , H. Hayashi , H. Murakami , T. Kato , S. Niho , M. Oki , H. Yoshioka , H. Daga , K. Azuma , S. Miura , K. Nishino , M. Satouchi , I. Okamoto , N. Yamamoto\",\"doi\":\"10.1016/S1556-0864(25)00233-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S34-S35\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425002333\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425002333","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
38P: Two years of follow-up data of a phase II clinical trial of atezolizumab with bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung cancer (WJOG10718L/@ Be Study)
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.